Gilead Sciences (GILD - Free Report) closed at $76.29 in the latest trading session, marking a +0.9% move from the prior day. This move outpaced the S&P 500's daily loss of 0.44%. Elsewhere, the Dow lost 0.53%, while the tech-heavy Nasdaq lost 0.26%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 2.93% over the past month, lagging the Medical sector's gain of 5.37% and the S&P 500's gain of 3.59% in that time.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 28.63%. Our most recent consensus estimate is calling for quarterly revenue of $5.38 billion, down 17.31% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.57 per share and revenue of $21.58 billion, which would represent changes of -25.68% and -17.32%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for GILD. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 11.51. For comparison, its industry has an average Forward P/E of 29.49, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.